Cerevel Therapeutics Inc., a Pfizer joint venture focusing on neurological diseases, said Thursday that it was being taken public by a blank check company backed by Perceptive Advisors in a $780 million merger. The Goodwin life sciences team representing Cervel Therapeutics was led by Stuart Cable, Art McGivern, James Xu and John Mei, and the Goodwin SPAC team was led by Jocelyn Arel and Dan Espinoza. Read the article in Law360 here.
In The Press
July 30, 2020